<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02760407</url>
  </required_header>
  <id_info>
    <org_study_id>CL04041023</org_study_id>
    <nct_id>NCT02760407</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease</brief_title>
  <acronym>CREDO 2</acronym>
  <official_title>A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R-Pharm International, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>OCT Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>R-Pharm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine how effective and safe the study drug Olokizumab&#xD;
      is, in patients with Rheumatoid Arthritis (RA) who are already receiving, but not fully&#xD;
      responding to treatment with methotrexate (MTX).&#xD;
&#xD;
      The primary objective of this study was to evaluate the efficacy of OKZ 64 mg administered&#xD;
      subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) relative to placebo&#xD;
      in subjects with moderately to severely active RA inadequately controlled by MTX therapy&#xD;
&#xD;
      The secondary objective was to evaluate the efficacy of OKZ relative to adalimumab in&#xD;
      subjects with moderately to severely active RA inadequately controlled by MTX therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this Phase III study was to assess the efficacy, safety and tolerability of OKZ&#xD;
      in subjects with moderately to severely active RA who have responded inadequately to MTX. The&#xD;
      primary endpoint of the trial was at Week 12. Olokizumab was expected to reduce the disease&#xD;
      activity and improve physical function. The study was expected to provide safety information&#xD;
      in a large group of subjects over at least a 24 week period.&#xD;
&#xD;
      This study included a 4-week Screening Period, a double-blind Treatment Period from Week 0 to&#xD;
      Week 24, and a Safety Follow-Up Period from Week 24 to Week 44. Subjects were assessed for&#xD;
      eligibility to enter the study during the 4-week Screening Period. A total of 1575 subjects&#xD;
      were planned to be randomly assigned to 1 of 4 treatment groups in a 2:2:2:1 ratio (450, 450,&#xD;
      450, and 225 subjects per group, respectively):&#xD;
&#xD;
        1. Olokizumab 64 mg q4w: SC injection of OKZ 64 mg q4w (alternating with SC injection of&#xD;
           placebo q4w to maintain blinding) + MTX&#xD;
&#xD;
        2. Olokizumab 64 mg q2w: SC injection of OKZ 64 mg q2w + MTX&#xD;
&#xD;
        3. Adalimumab 40 mg q2w: SC injection of adalimumab 40 mg q2w + MTX&#xD;
&#xD;
        4. Placebo: SC injection of placebo q2w + MTX&#xD;
&#xD;
      Throughout the double-blind Treatment Period, all subjects were required to remain on a&#xD;
      stable dose of background MTX with a stable route of administration. Concomitant treatment&#xD;
      with folic acid was required for all subjects. The last dose of study treatment (OKZ,&#xD;
      adalimumab, or placebo) was at Week 22 in all groups.&#xD;
&#xD;
      Following Visit 2 (randomization; Week 0), subjects returned to the study site at least every&#xD;
      2 weeks through Week 24 for response and safety assessments.&#xD;
&#xD;
      At Week 14, subjects who did not improve by at least 20% in both swollen and tender joint&#xD;
      counts were classified as nonresponders and were administered sulfasalazine and/or&#xD;
      hydroxychloroquine as rescue medication in addition to the assigned treatment.&#xD;
&#xD;
      After completion of the 24-week double-blind Treatment Period, subjects either rolled over&#xD;
      into the long-term open-label extension (OLE) study or entered the Safety Follow-Up Period.&#xD;
      During the Safety Follow-Up Period, subjects returned for visits +4, +8, and +22 weeks after&#xD;
      the last dose of study treatment.&#xD;
&#xD;
      Subjects who discontinued randomized treatment prematurely were required to come for the End&#xD;
      of Treatment (EoT) Visit 2 weeks after the last study treatment administration and then&#xD;
      continue with the scheduled study visits.&#xD;
&#xD;
      Adverse events (AEs) were assessed throughout the study (starting when the subject signed the&#xD;
      informed consent form) and evaluated using the Common Terminology Criteria for Adverse Events&#xD;
      Version 4.0. There was ongoing monitoring of safety events, including laboratory findings, by&#xD;
      the Sponsor or the Sponsor's designee. In addition, safety was assessed throughout the study&#xD;
      by an independent Data Safety Monitoring Board and potential major adverse cardiac events&#xD;
      were evaluated by an independent Cardiovascular Adjudication Committee.&#xD;
&#xD;
      The study was conducted at 209 sites across 18 countries globally (in US, European Union&#xD;
      (EU),United Kingdom (UK), Russian Federation, Asia, Latin America)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 24, 2016</start_date>
  <completion_date type="Actual">November 5, 2019</completion_date>
  <primary_completion_date type="Actual">August 2, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ACR20 Response</measure>
    <time_frame>at Week 12</time_frame>
    <description>The difference between OKZ and placebo in the percentage of subjects achieving an ACR20 response and remaining on randomized treatment and in the study at Week 12. (where a responder is defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12) This endpoint will serve to demonstrate that the efficacy of OKZ is superior to placebo. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures:&#xD;
Patient Global Assessment of Disease Activity (VAS)&#xD;
Patient Assessment of Pain (VAS)&#xD;
HAQ-DI&#xD;
Physician Global Assessment (VAS)&#xD;
Level of acute phase reactant (CRP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR20 Response and to Demonstrate That the Efficacy of OKZ is Non-inferior to Adalimumab</measure>
    <time_frame>at Week 12</time_frame>
    <description>Where a responder is defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12. This endpoint will serve to demonstrate that the efficacy of OKZ is non-inferior to adalimumab, provided that superiority of adalimumab to placebo (assay sensitivity) is demonstrated concurrently based on the same endpoint.&#xD;
American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures:&#xD;
Patient Global Assessment of Disease Activity (VAS)&#xD;
Patient Assessment of Pain (VAS)&#xD;
HAQ-DI&#xD;
Physician Global Assessment (VAS)&#xD;
Level of acute phase reactant (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference Between OKZ and Placebo in the Percentage of Subjects Achieving Low Disease Activity</measure>
    <time_frame>at Week 12</time_frame>
    <description>Defined as Disease Activity Score 28-joint count (DAS28) C-reactive protein (CRP) &lt;3.2, and remaining on randomized treatment and in the study at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference Between Adalimumab and OKZ in Percentage of Subjects Achieving Low Disease Activity, Defined as DAS28 (CRP) &lt;3.2</measure>
    <time_frame>at Week 12</time_frame>
    <description>Percentage of subjects achieving low disease activity, defined as DAS28 (CRP) &lt;3.2, and remaining on randomized treatment and in the study at Week 12; served to demonstrate that the efficacy of OKZ was noninferior to adalimumab, provided that superiority of adalimumab to placebo (assay sensitivity) was demonstrated concurrently based on the same endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Difference between OKZ and placebo in the improvement of physical ability. Improvement of physical ability from baseline to week 12, as measured by HAQ-DI. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3 where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question.A decrease from baseline indicates improvement for HAQ-DI. The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. The HAQ-DI total score ranges from 0 to 3, with higher scores indicating greater disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR50 Response</measure>
    <time_frame>at Week 24</time_frame>
    <description>Difference between OKZ and placebo in the percentage of subjects achieving an ACR50 response and remaining on randomized treatment and in the study at Week 24 American College of Rheumatology 50% Response is a composite defined as ≥50%, improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥50%, improvement from baseline in at least 3 of the 5 remaining core set measures:&#xD;
Patient Global Assessment of Disease Activity (VAS)&#xD;
Patient Assessment of Pain (VAS)&#xD;
HAQ-DI&#xD;
Physician Global Assessment (VAS)&#xD;
Level of acute phase reactant (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Disease Activity Index (CDAI) ≤2.8 (Remission)</measure>
    <time_frame>at Week 24</time_frame>
    <description>Difference between OKZ and placebo in the percentage of subjects with Clinical Disease Activity Index (CDAI) ≤2.8 (remission) and remaining on randomized treatment and in the study at Week 24</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1648</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Arm 1: Olokizumab q4w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olokizumab 64 mg subcutaneous q4w +placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Olokizumab q2w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olokizumab 64mg subcutaneous q2w + Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Adalimumab q2w</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adalimumab 40mg q2w subcutaneous + Methotrexate&#xD;
Subjects were administered adalimumab 40 mg q2w via SC injection as an active comparator+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: Placebo q2w</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo q2w subcutaneous + Methotrexate&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olokizumab 64mg q4w</intervention_name>
    <description>160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial, containing a target fill volume of 1.1 mL (for withdrawal of not less than 0.8 mL) or a target fill volume of 0.5 mL (for withdrawal of not less than 0.4 mL)</description>
    <arm_group_label>Arm 1: Olokizumab q4w</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olokizumab 64mg q2w</intervention_name>
    <description>160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial</description>
    <arm_group_label>Arm 2: Olokizumab q2w</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab 40mg q2w</intervention_name>
    <description>0.4 or 0.8 mL prefilled, single-dose syringe</description>
    <arm_group_label>Arm 3: Adalimumab q2w</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo q2w</intervention_name>
    <description>sodium chloride 0.9% solution supplied in either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule</description>
    <arm_group_label>Arm 1: Olokizumab q4w</arm_group_label>
    <arm_group_label>Arm 4: Placebo q2w</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects willing and able to sign informed consent&#xD;
&#xD;
          -  Subjects must have a diagnosis of adult onset RA classified by ACR/EULAR 2010 revised&#xD;
             classification criteria for RA for at least 12 weeks prior to Screening. (If the&#xD;
             subject was diagnosed according to ACR 1987 criteria previously, the Investigator may&#xD;
             classify the subject per ACR 2010 retrospectively, using available source data)&#xD;
&#xD;
          -  Inadequate response to treatment with MTX for at least 12 weeks prior to Screening at&#xD;
             a dose of 15 to 25 mg/week (or ≥10 mg/week if intolerant to higher doses) (The dose&#xD;
             and means of administering MTX must have been stable for at least 6 weeks prior to&#xD;
             Screening.)&#xD;
&#xD;
          -  Subjects must be willing to take folic acid or equivalent throughout the study.&#xD;
&#xD;
          -  Subjects must have moderately to severely active RA disease as defined by all of the&#xD;
             following:&#xD;
&#xD;
               -  ≥6 tender joints (68 joint count) at Screening and baseline; and&#xD;
&#xD;
               -  ≥6 swollen joints (66 joint count) at Screening and baseline; and&#xD;
&#xD;
               -  CRP above ULN at Screening based on the central laboratory results&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of any other inflammatory arthritis or systemic rheumatic disease (e.g.,&#xD;
             gout, psoriatic or reactive arthritis, Crohn's disease, Lyme disease, juvenile&#xD;
             idiopathic arthritis, or systemic lupus erythematosus);However, subjects may have&#xD;
             secondary Sjogren's syndrome or hypothyroidism.&#xD;
&#xD;
          -  Subjects who are Steinbrocker class IV functional capacity (incapacitated, largely or&#xD;
             wholly bed-ridden or confined to a wheelchair, with little or no self-care)&#xD;
&#xD;
          -  Prior exposure to any licensed or investigational compound directly or indirectly&#xD;
             targeting IL 6 or IL 6R (including tofacitinib or other Janus kinases and spleen&#xD;
             tyrosine kinase [SYK] inhibitors)&#xD;
&#xD;
          -  Prior treatment with cell depleting therapies including anti CD20 or investigational&#xD;
             agents (e.g., CAMPATH, anti CD4, anti CD5, anti CD3, and anti CD19)&#xD;
&#xD;
          -  Prior use of bDMARDs&#xD;
&#xD;
          -  Use of parenteral and/or intra-articular glucocorticoids within 4 weeks prior to&#xD;
             baseline&#xD;
&#xD;
          -  Use of oral glucocorticoids greater than 10 mg/day prednisone (or equivalent) or&#xD;
             change in dosage within 2 weeks prior to baseline&#xD;
&#xD;
          -  Prior documented history of no response to hydroxychloroquine and sulfasalazine&#xD;
&#xD;
          -  Prior use of cDMARDs (other than MTX) within the following windows prior to baseline&#xD;
             (cDMARDs should not be discontinued to facilitate a subject's participation in the&#xD;
             study, but should instead have been previously discontinued as part of a subject's&#xD;
             medical management of RA):&#xD;
&#xD;
               1. 4 weeks for sulfasalazine, azathioprine, cyclosporine, hydroxychloroquine,&#xD;
                  chloroquine, gold, penicillamine, minocycline, or doxycycline&#xD;
&#xD;
               2. 12 weeks for leflunomide unless the subject has completed the following&#xD;
                  elimination procedure at least 4 weeks prior to baseline: Cholestyramine at a&#xD;
                  dosage of 8 grams 3 times daily for at least 24 hours, or activated charcoal at a&#xD;
                  dosage of 50 grams 4 times daily for at least 24 hours&#xD;
&#xD;
               3. 24 weeks for cyclophosphamide&#xD;
&#xD;
          -  Vaccination with live vaccines in the 6 weeks prior to baseline or planned vaccination&#xD;
             with live vaccines during the study&#xD;
&#xD;
          -  Participation in any other investigational drug study within 30 days or 5 times the&#xD;
             terminal half-life of the investigational drug, whichever is longer, prior to baseline&#xD;
&#xD;
          -  Other treatments for RA (e.g., Prosorba Device/Column) within 6 months prior to&#xD;
             baseline&#xD;
&#xD;
          -  Use of intra-articular hyaluronic acid injections within 4 weeks prior to baseline&#xD;
&#xD;
          -  Use of non-steroidal anti-inflammatory drugs (NSAIDs) on unstable dose or switching of&#xD;
             NSAIDs within 2 weeks prior to baseline&#xD;
&#xD;
          -  Previous participation in this study (randomized) or another study of OKZ&#xD;
&#xD;
          -  Abnormal laboratory values as defined below:&#xD;
&#xD;
               1. Creatinine level ≥ 1.5 mg/dL (132 µmol/L) for females or ≥ 2.0 mg/dL (177 µmol/L)&#xD;
                  for males&#xD;
&#xD;
               2. ALT or AST level ≥ 1.5× ULN&#xD;
&#xD;
               3. Platelets &lt;100×10^9/L (&lt;100,000/mm^3)&#xD;
&#xD;
               4. White blood cell count &lt;3.5×10^9/L&#xD;
&#xD;
               5. Neutrophil count &lt;2000×10^6/L (&lt;2000/mm^3)&#xD;
&#xD;
               6. Hemoglobin level ≤ 80 g/L&#xD;
&#xD;
               7. Glycosylated hemoglobin (HbA1c) level ≥ 8%&#xD;
&#xD;
          -  Subjects with concurrent acute or chronic viral hepatitis B or C infection as detected&#xD;
             by blood tests at Screening(e.g., positive for hepatitis B surface antigen [HBsAg],&#xD;
             total hepatitis B core antibody [anti-HBc], or hepatitis C virus antibody [HCV Ab])&#xD;
&#xD;
             a) Subjects who are are positive for hepatitis B surface antibodies (anti-HBs), but&#xD;
             negative for HBsAg and anti-HBc, will be eligible&#xD;
&#xD;
          -  Subjects with HIV infection&#xD;
&#xD;
          -  Subjects with:&#xD;
&#xD;
               1. Suspected or confirmed current active TB disease or a history of active TB&#xD;
                  disease&#xD;
&#xD;
               2. Close contact (i.e., sharing the same household or other enclosed environment,&#xD;
                  such as a social gathering place, workplace, or facility, for extended periods&#xD;
                  during the day) with an individual with active TB within 1.5 years prior to&#xD;
                  Screening&#xD;
&#xD;
               3. History of untreated latent TB infection (LTBI), regardless of IGRA result at&#xD;
                  Screening&#xD;
&#xD;
             i. Subjects with a history of untreated LTBI may be re-screened and enrolled if they&#xD;
             fulfill all 3 of the following criteria:&#xD;
&#xD;
               1. Active TB is ruled out by a certified TB specialist or pulmonologist who is&#xD;
                  familiar with diagnosing and treating TB (as acceptable per local practice);&#xD;
&#xD;
               2. The subject has completed at least 30 days of LTBI-appropriate prophylaxis prior&#xD;
                  to baseline with agents recommended as preventative therapy for LTBI according to&#xD;
                  country-specific/Centers for Disease Control and Prevention (CDC) guidelines&#xD;
                  (treatment with isoniazid for 6 months is not an appropriate prophylactic regime&#xD;
                  for this study and it should not be used); and&#xD;
&#xD;
               3. The subject is willing to complete the entire course of recommended LTBI therapy&#xD;
                  d. Positive interferon-gamma release assay (IGRA) result at Screening. If&#xD;
                  indeterminate, the IGRA can be repeated once during the Screening Period. If&#xD;
                  there is a second indeterminate result, the subject will be excluded i. Subjects&#xD;
                  with a positive IGRA result at Screening may be re-screened and enrolled if they&#xD;
                  fulfill all 3 of the following criteria&#xD;
&#xD;
               1. Active TB is ruled out by a certified TB specialist or pulmonologist who is&#xD;
                  familiar with diagnosing and treating TB (as acceptable per local practice);&#xD;
&#xD;
               2. The subject has completed at least 30 days of LTBI-appropriate prophylaxis prior&#xD;
                  to baseline with agents recommended as preventative therapy for LTBI according to&#xD;
                  country-specific/CDC guidelines (treatment with isoniazid for 6 months is not an&#xD;
                  appropriate prophylactic regime for this study and it should not be used); and&#xD;
&#xD;
               3. The subject is willing to complete the entire course of recommended LTBI therapy&#xD;
                  ii. If a subject with a positive IGRA result at Screening has documented evidence&#xD;
                  of completing treatment for LTBI with a treatment regime and treatment duration&#xD;
                  that are appropriate for this study, the subject may be enrolled without further&#xD;
                  prophylaxis if recommended by a certified TB specialist or pulmonologist who is&#xD;
                  familiar with diagnosing and treating TB (as acceptable per local practice) and&#xD;
                  no new exposure in close contact with an individual with active TB after&#xD;
                  completing the prophylactic treatment is suspected&#xD;
&#xD;
          -  Concurrent malignancy or a history of malignancy within the last 5 years (with the&#xD;
             exception of successfully treated carcinoma of the cervix in situ and successfully&#xD;
             treated basal cell carcinoma and squamous cell carcinoma not less than 1 year prior to&#xD;
             Screening [and no more than 3 excised skin cancers within the last 5 years prior to&#xD;
             Screening])&#xD;
&#xD;
          -  Subjects with any of the following CV conditions:&#xD;
&#xD;
               1. Uncompensated congestive heart failure, or class III or IV heart failure defined&#xD;
                  by the New York Heart Association classification (The Criteria Committee of the&#xD;
                  New York Heart Association, 1994)&#xD;
&#xD;
               2. Untreated or resistant arterial hypertension Grade II-III (systolic blood&#xD;
                  pressure (BP) &gt;100 mm Hg)&#xD;
&#xD;
               3. History or presence of concurrent severe and/or uncontrolled CV disorder&#xD;
                  (including but not limited to acute coronary syndrome or stroke/transient&#xD;
                  ischemic attack in the previous 3 months before Screening) that would, in the&#xD;
                  Investigator's judgment, contraindicate subject participation in the clinical&#xD;
                  study, or clinically significant enough in the opinion of the Investigator to&#xD;
                  alter the disposition of the study treatment, or constitute a possible&#xD;
                  confounding factor for assessment of efficacy or safety of the study treatment&#xD;
&#xD;
          -  Subjects with a history or presence of any concurrent severe and/or uncontrolled&#xD;
             medical condition (including but not limited to respiratory, hepatic, renal, GI,&#xD;
             endocrinological, dermatological, neurological, psychiatric, hematological (including&#xD;
             bleeding disorder), or immunologic/immunodeficiency disorder(s) ) that would, in the&#xD;
             Investigator's judgment, contraindicate subject participation in the clinical study,&#xD;
             or clinically significant enough in the opinion of the Investigator to alter the&#xD;
             disposition of the study treatment, or constitute a possible confounding factor for&#xD;
             assessment of efficacy or safety of the study treatment&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Subjects with any infection requiring oral antibiotic or antiviral therapy in the 2&#xD;
             weeks prior to Screening or at baseline, injectable anti-infective therapy in the last&#xD;
             4 weeks prior to baseline, or serious or recurrent infection with history of&#xD;
             hospitalization in the 6 months prior to baseline&#xD;
&#xD;
          -  Subjects with evidence of disseminated herpes zoster infection, zoster encephalitis,&#xD;
             meningitis, or other non-self-limited herpes zoster infections in the 6 months prior&#xD;
             to baseline&#xD;
&#xD;
          -  Subjects with planned surgery during the study or surgery ≤ 4 weeks prior to Screening&#xD;
             and from which the subject has not fully recovered, as judged by the Investigator&#xD;
&#xD;
          -  Subjects with diverticulitis or other symptomatic GI conditions that might predispose&#xD;
             the subject to perforations, including subjects with history of such predisposing&#xD;
             conditions (e.g., diverticulitis, GI perforation, or ulcerative colitis)&#xD;
&#xD;
          -  Pre-existing central nervous system demyelinating disorders (e.g., multiple sclerosis&#xD;
             and optic neuritis)&#xD;
&#xD;
          -  History of chronic alcohol or drug abuse as judged by the Investigator&#xD;
&#xD;
          -  Female subjects who are pregnant, currently lactating, have lactated within the last&#xD;
             12 weeks, or who are planning to become pregnant during the study or within 6 months&#xD;
             of last dose of study treatment&#xD;
&#xD;
          -  Female subjects of childbearing potential (unless permanent cessation of menstrual&#xD;
             periods, determined retrospectively after a woman has experienced 12 months of natural&#xD;
             amenorrhea as defined by the amenorrhea with underlying status (e.g., correlative age)&#xD;
             or 6 months of natural amenorrhea with documented serum follicle-stimulating hormone&#xD;
             levels &gt;40 mIU/mL and estradiol &lt;20 pg/mL) who are not willing to use a highly&#xD;
             effective method of contraception during the study and for at least 6 months after the&#xD;
             last administration of study treatment&#xD;
&#xD;
        OR&#xD;
&#xD;
        Male subjects with partners of childbearing potential not willing to use a highly effective&#xD;
        method of contraception during the study and for at least 3 months after the last&#xD;
        administration of study treatment&#xD;
&#xD;
        Highly effective contraception is defined as:&#xD;
&#xD;
          1. Female sterilization surgery: hysterectomy, surgical bilateral oophorectomy (with or&#xD;
             without hysterectomy), or tubal ligation at least 6 weeks prior to the first dose of&#xD;
             study treatment&#xD;
&#xD;
               -  In the case of oophorectomy alone, only when the reproductive status of the woman&#xD;
                  has been confirmed by documented follow-up hormone level assessment&#xD;
&#xD;
          2. Total abstinence if it is the preferred and constant lifestyle of the subject. Thus,&#xD;
             periodic abstinence such as ovulation, symptothermal, postovulation, calendar methods,&#xD;
             and withdrawal are not acceptable methods of contraception&#xD;
&#xD;
          3. Male sterilization surgery: at least 6 months prior to Screening (with the appropriate&#xD;
             postvasectomy documentation of the absence of sperm in the ejaculate). For female&#xD;
             subjects, the vasectomized male should be the only partner.&#xD;
&#xD;
          4. Placement of established intrauterine device (IUD): IUD copper or IUD with&#xD;
             progesterone&#xD;
&#xD;
          5. Barrier method (condom and intravaginal spermicide, cervical caps with spermicide,&#xD;
             diaphragma with spermicide) in combination with the following: established oral,&#xD;
             injected, or implanted hormone methods of contraception or contraceptive patch&#xD;
&#xD;
               -  Subjects with a known hypersensitivity to any component of the OKZ drug product,&#xD;
                  adalimumab, or placebo&#xD;
&#xD;
               -  Subjects with a known hypersensitivity or contraindication to any component of&#xD;
                  the rescue medication&#xD;
&#xD;
               -  History of severe allergic or anaphylactic reactions to human, humanized, or&#xD;
                  murine monoclonal antibodies&#xD;
&#xD;
               -  Subject's unwillingness or inability to follow the procedures outlined in the&#xD;
                  protocol&#xD;
&#xD;
               -  Other medical or psychiatric conditions or laboratory abnormalities that may&#xD;
                  increase potential risk associated with study participation and administration of&#xD;
                  investigational products, or that may affect study results interpretation and, as&#xD;
                  per the Investigator's judgment, make the subject ineligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikhail Samsonov</last_name>
    <role>Study Director</role>
    <affiliation>R-Pharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Associates, P.C.</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Associates, P.C.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Research, PLLC</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91722</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriWest Research Associates</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Center of San Diego</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Med Corp.</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <zip>92543</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research, LLC</name>
      <address>
        <city>La Palma</city>
        <state>California</state>
        <zip>90623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valerius Medical Group</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Bay Rheumatology Medical Group, Inc.</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94578</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Arthritis Center Medical Grpoup</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Rheumatology Clinical Trials</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nazanin Firooz, MD Inc.</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <zip>91607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Arthritis Clinic</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Osteoporosis Center PC</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Research Associates LLC</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware Arthritis</name>
      <address>
        <city>Lewes</city>
        <state>Delaware</state>
        <zip>19958</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Javed Rheumatology Associates</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RASF - Clinical Research Center</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reliable Clinical Research, LLC</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmax Research Clinic, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Medical Center &amp; Research Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Center of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research Inc.</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Research of Florida, Inc.</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Clinical Trials, LLC.</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McIlwain Medical Group, PA</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AdventHealth Medical Group, PA</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources, Inc.</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <zip>34292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center of North Georgia</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marietta Rheumatology Associates, PC</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Arthritis Research</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>IL 60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Springfield Clinic, LLP</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute, Inc.</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Graves Gilbert Clinic</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis &amp; Diabetes Clinic, Inc.</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klein and Associates, M.D., P.A.</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology and Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AA MRC LLC Ahmed Arif Medical Research Center</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North MS Medical Clinics, Inc.</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glacier View Research Instutute-Rheumatology</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician Resrch Collaboration</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westroads Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allied Clinical Research</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Osteoporosis Associates, PA</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone ambulatory care</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medication Management, LLC</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cape Fear Arthritis Care</name>
      <address>
        <city>Leland</city>
        <state>North Carolina</state>
        <zip>28451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Medical Group</name>
      <address>
        <city>Minot</city>
        <state>North Dakota</state>
        <zip>58701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>STAT Research, Inc.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Source, Inc.</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Oklahoma, PLLC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research, P.C.</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Low Country Rheumatology, PA</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amarillo Center for Clinical Research</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Regional Clinic, P.A.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Management LLC</name>
      <address>
        <city>Baytown</city>
        <state>Texas</state>
        <zip>77521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions, Inc.</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Comprehensive Clinical Research Solutions</name>
      <address>
        <city>Grapevine</city>
        <state>Texas</state>
        <zip>76034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Clinic of Houston, P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Mgmt, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Mangemnt LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Rheumatology of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77382</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research, Inc.</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <zip>77573</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology, Internal Medicine</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Alex De Jesus Rheumatology, P.A.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest, PLLC</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano Regional del Sur</name>
      <address>
        <city>Bahia Blanca</city>
        <state>Buenos Aires</state>
        <zip>B8001HXM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Medicas Mar del Plata</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7600FYK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clinicas-Mar del Plata</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7600FZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Medico CER</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <zip>B1878DVB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Higado y Aparato Digestivo</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio San Martin</name>
      <address>
        <city>Venado Tuerto</city>
        <state>Santa Fe</state>
        <zip>S2600KUE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Privado de Reumatologia</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Reumatológicas</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <zip>T4000BRD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Asistencia</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1646DBM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute Investigaciones Clinc Quilme</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1878GEG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Organizacion Medica de Investigacion (OMI)</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APRILLUS</name>
      <address>
        <city>Ciudad Autonoma Buenos aires</city>
        <zip>C1046AAQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Centenario</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1204AAD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atencion Integral en Reumatologia (AIR)</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1426AAL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto DAMIC Fundacion Rusculleda</name>
      <address>
        <city>Cordoba</city>
        <zip>X5003DCE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Privado Centro</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Polivalente de Asistencia e Inv. Clinica CER</name>
      <address>
        <city>San Juan</city>
        <zip>J5402DIL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUWC - UFC - Hospital Universitário Walter Cantídio - Universidade Federal do Ceará</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <zip>60430-370</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEDOES - Diagnóstico e Pesquisa</name>
      <address>
        <city>Vitória</city>
        <state>Espírito Santo</state>
        <zip>29055-450</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIP - Centro Internacional de Pesquisa</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <zip>74110-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMiP - Centro Mineiro de Pesquisa</name>
      <address>
        <city>Juiz de Fora</city>
        <state>Minas Gerais</state>
        <zip>36010-570</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CETI - Centro de Estudos em Terapias Inovadoras Ltda.</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80030-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinilive - Clínica do Idoso e Pesquisa Clínica</name>
      <address>
        <city>Maringá</city>
        <state>Paraná</state>
        <zip>87015-180</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Bruno Born</name>
      <address>
        <city>Lajeado</city>
        <state>Rio Grande Do Sul</state>
        <zip>95900-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Vicente de Paulo</name>
      <address>
        <city>Passo Fundo</city>
        <state>Rio Grande Do Sul</state>
        <zip>99010-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMK Serviços Médicos S/S Ltda</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90480-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo André</city>
        <state>Sao Paulo</state>
        <zip>09060-870</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Estadual Mário Covas</name>
      <address>
        <city>Santo André</city>
        <state>Sao Paulo</state>
        <zip>9190510</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUCFF-UFRJ - Hospital Universitário Clementino Fraga Filho - Universidade Federal do Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Brasil Centro de Pesquisas e Análises Clínicas Ltda.</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22271-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica de Neoplasias Litoral</name>
      <address>
        <city>Santa Catarina</city>
        <zip>88301-220</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CPCLIN - Centro de Pesquisas Clínicas Ltda.</name>
      <address>
        <city>São Paulo</city>
        <zip>01228-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Abreu Sodré - AACD</name>
      <address>
        <city>São Paulo</city>
        <zip>04023-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT Pulmed OOD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT - Ruse, AD</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinski Zentar-1-Sevlievo EOOD</name>
      <address>
        <city>Sevlievo</city>
        <zip>5400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT - Shumen, AD</name>
      <address>
        <city>Shumen</city>
        <zip>9700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Excelsior&quot;, OOD</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NMTH &quot;Tsar Boris III&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Lyulin&quot;, EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1336</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT Sv. Ivan Rilski EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC Synexus - Sofia EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MDHAT 'Dr. Stefan Cherkezov', AD</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Medico</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobón Uribe</name>
      <address>
        <city>Antioquia</city>
        <zip>050034</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Instituto de Reumatologia Fernando Chalem</name>
      <address>
        <city>Bogota</city>
        <zip>111211</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion en Reumatologia y Especialidades Medicas SAS. CIREEM</name>
      <address>
        <city>Bogotá</city>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicity S.A.S.</name>
      <address>
        <city>Bucaramanga</city>
        <zip>680003</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Artritis Temprana S.A.</name>
      <address>
        <city>Cali</city>
        <zip>76001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Brno s.r.o</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologie s.r.o.</name>
      <address>
        <city>Brno</city>
        <zip>638 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicka ambulance</name>
      <address>
        <city>Jihlava</city>
        <zip>586 33</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicka a interni ambulance</name>
      <address>
        <city>Kladno</city>
        <zip>272 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTCenter MaVe s.r.o.</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artroscan s.r.o.</name>
      <address>
        <city>Ostrava - Trebovice</city>
        <zip>722 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vesalion s.r.o.</name>
      <address>
        <city>Ostrava</city>
        <zip>70200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARTHROHELP s.r.o.</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Pardubice</name>
      <address>
        <city>Pardubice</city>
        <zip>53002</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clintrial, s.r.o.</name>
      <address>
        <city>Praha 10</city>
        <zip>120 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Praha</name>
      <address>
        <city>Praha 1</city>
        <zip>101 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicka ambulance</name>
      <address>
        <city>Praha 4 Nusle</city>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuselska poliklinika</name>
      <address>
        <city>Praha 4</city>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav</name>
      <address>
        <city>Praha</city>
        <zip>128 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affidea Praha, s.r.o.</name>
      <address>
        <city>Praha</city>
        <zip>148 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDICAL PLUS s.r.o.</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PV - Medical, s.r.o.</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>11312</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medita Kliinik OÜ</name>
      <address>
        <city>Tartu</city>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik gGmbH</name>
      <address>
        <city>Bad Nauheim</city>
        <state>Hessen</state>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIRI - Centrum für Innovative Diagnostik und Therapie GmbH</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMO.MD GmbH</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumapraxis Dr. med. Reiner Kurthen</name>
      <address>
        <city>Aachen</city>
        <state>Westfalen</state>
        <zip>D 52064</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin Dpt. of Dermatology Venerology and Allergology</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Berlin-Mitte GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HRF Hamburger Rheuma Forschungszentrum</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienambulanz Dr. Wassenberg</name>
      <address>
        <city>Northeim</city>
        <zip>40878</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Principal SMO Kft.</name>
      <address>
        <city>Baja</city>
        <zip>H-6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRC Gyogyszervizsgalo Kozpont Kft.</name>
      <address>
        <city>Balatonfured</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinexpert Egeszsegugyi Szolg. es Ker. Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1033</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Obudai Egeszsegugyi Centrum</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiskunhalasi Semmelweis Korhaz</name>
      <address>
        <city>Kiskunhalas</city>
        <zip>6400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRC Szekesfehervar</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAV Korhaz és Rendelointezet</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital Medical Center</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Seoul Hosp</name>
      <address>
        <city>Seoul</city>
        <state>Seongdong-gu</state>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Chungbuk</city>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35233</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Center</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>13496</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeju National University Hospital</name>
      <address>
        <city>Jeju</city>
        <zip>63241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr.Saulite-Kandevica Private Practice</name>
      <address>
        <city>Liepaja</city>
        <zip>LV-3401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GK Neuroklinika</name>
      <address>
        <city>Riga</city>
        <zip>LV1024</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alytаus Regional S. Kudirkos Hospital, Public Institution</name>
      <address>
        <city>Alytus</city>
        <zip>62114</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Kaunas Hospital, Public Institution</name>
      <address>
        <city>Kaunas</city>
        <zip>45130</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaipeda University Hospital, Public Institution</name>
      <address>
        <city>Klaipeda</city>
        <zip>92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siauliai Republican Hospital, Public Institution</name>
      <address>
        <city>Siauliai</city>
        <zip>76231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santariskiu Clinic, Public Institution</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center Outpatient Clinic, Public Institution</name>
      <address>
        <city>Vilnius</city>
        <zip>LT01117</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clínica GRAMEL S.C</name>
      <address>
        <city>Mexico</city>
        <state>DisMexicotrito Federal</state>
        <zip>03720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinstile, S.A. de C.V.</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comite Mexicano Para la Prevencion de Osteoporosis AC</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>16100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinicos Asociados BOCM S.C.</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>3300</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute S.C.</name>
      <address>
        <city>Tlalnepantla</city>
        <state>Estado De Mexico</state>
        <zip>54055</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Investigacion en Reumatologia y Obesidad S.C.</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios de Investigacion Basica y Clinica SC</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelerium S. de R.L. de C.V.</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universidad Autonoma de Nuevo Leon, Hospital Universitario Dr. Jose Eleuterio Gonzalez</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigacion y Biomedicina de Chihuahua, S.C.</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Alta Especialidad en Reumatología e Investigación del Potosí, S.C.</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78213</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CERMED</name>
      <address>
        <city>Bialystok</city>
        <zip>15-270</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ ZDROWIE Osteo-Medic</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki nr 2 im.dr J. Biziela</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny nr 1 w Bytomiu</name>
      <address>
        <city>Bytom</city>
        <zip>41902</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McBk S.C.</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polimedica Centrum Badań, Profilaktyki I Leczenia</name>
      <address>
        <city>Kielce</city>
        <zip>25-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne AMED</name>
      <address>
        <city>Lodz</city>
        <zip>91-363</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ETYKA Osrodek Badan Klinicznych</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-117</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewodzki im. Prymasa Kardynala Stefana Wyszynskiego</name>
      <address>
        <city>Sieradz</city>
        <zip>98-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR - Lodz - PL</name>
      <address>
        <city>Skierniewice</city>
        <zip>90 368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Ogrodowa</name>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RCMed</name>
      <address>
        <city>Sochaczew</city>
        <zip>96-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne Staszow</name>
      <address>
        <city>Staszow</city>
        <zip>28-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ Tomaszow Lubelski</name>
      <address>
        <city>Tomaszow Lubelski</city>
        <zip>22-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej &quot;Nasz Lekarz&quot; Praktyka Grupowa Lekarzy Rodzinnych z</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medycyna Kliniczna</name>
      <address>
        <city>Warszawa</city>
        <zip>00-874</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheuma Medicus Zaklad Opieki Zdrowotnej</name>
      <address>
        <city>Warszawa</city>
        <zip>02-118</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McM Polimedica</name>
      <address>
        <city>Wysokie Mazowieckie</city>
        <zip>02777</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne Zamosc</name>
      <address>
        <city>Zamosc</city>
        <zip>22-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;POLIMEDICA Centrum Badan</name>
      <address>
        <city>Zgierz</city>
        <zip>95-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta &quot;Sf. Apostol Andrei&quot; Constanta</name>
      <address>
        <city>Constanta</city>
        <zip>900591</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mediab SRL</name>
      <address>
        <city>Targu Mures</city>
        <zip>540142</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital 4</name>
      <address>
        <city>Barnaul</city>
        <state>Altai Region</state>
        <zip>656055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for War Veterans</name>
      <address>
        <city>Kemerovo</city>
        <state>Kemerowo Oblast</state>
        <zip>650000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kursk Clinical Hospital</name>
      <address>
        <city>Kursk</city>
        <state>Kursk Oblast</state>
        <zip>305507</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center n a Almazov</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Leningrad Oblast</state>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPb SBHI &quot;Clinical Rheumatological Hospital #25&quot;, Fourth Rheumatology Unit</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Leningradskaya Oblast</state>
        <zip>190068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBEI HE &quot;FMSMU n.a. I.M. Sechenov of MoH of RF&quot;, University Hospital #2, Departament of New Drugs Introduction</name>
      <address>
        <city>Moscow</city>
        <state>Moscovskaya Oblast</state>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital 3</name>
      <address>
        <city>Moscow</city>
        <state>Moscow Oblast</state>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital 1</name>
      <address>
        <city>Moscow</city>
        <state>Moscow Oblast</state>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution &quot;City Clinical Hospital # 15 n.a O.M. Filatov&quot; of Moscow Healtheare Department</name>
      <address>
        <city>Moscow</city>
        <state>Moscow Region</state>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI of Nizhny Novgorod Region &quot;Nizhny Novgorod Regional Clinical Hospital n.a.Semashko&quot;</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <state>Nizhegorodskaya Oblast</state>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Therapy</name>
      <address>
        <city>Novosibirsk</city>
        <state>Novosibirsk Oblast</state>
        <zip>630089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital 1</name>
      <address>
        <city>Novosibirsk</city>
        <state>Novosibirsk Oblast</state>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital n a Kuvatov</name>
      <address>
        <city>Ufa</city>
        <state>Republic Of Bashkortostan</state>
        <zip>450005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI of Republic of Karelia &quot;Republican Hospital named after V.A.Baranov&quot;</name>
      <address>
        <city>Petrozavodsk</city>
        <state>Republic Of Karelia</state>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-govarnmental Healtheare Institution &quot;Regional Clinical Hospital at Smolensk station of OJSC &quot;Russian Railways&quot;</name>
      <address>
        <city>Smolensk</city>
        <state>Smolenskaya Oblast</state>
        <zip>214025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavropol Clinical Hospital</name>
      <address>
        <city>Stavropol</city>
        <state>Stavropol Krai</state>
        <zip>355000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Sverdlovsk Region &quot;Sverdlovsk Regional Clinical Hospital #1&quot;</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Sverdlovskaya Oblast</state>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBEI HPE &quot;Ural State Medical University&quot; of MoH of RF based MBI &quot;Central City Clinical Hospital #6&quot;</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Sverdlovskaya Oblast</state>
        <zip>620149</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Autonomous Healthcare Institution &quot;Republican Clinical Hospital of Ministry of Health of Tatarstan Republic</name>
      <address>
        <city>Kazan'</city>
        <state>The Republic Of Tatarstan</state>
        <zip>420064</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Vladimir</city>
        <state>Vladimir Oblast</state>
        <zip>600023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;University n a Burdenko</name>
      <address>
        <city>Voronezh</city>
        <state>Voronezh Oblast</state>
        <zip>394066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaroslavl Clinical Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <state>Yaroslavl Oblast</state>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute n a Nasonova</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center</name>
      <address>
        <city>Tainan</city>
        <zip>710</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Linkou</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torbay Hospital</name>
      <address>
        <city>Torquay</city>
        <state>Devon</state>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whipps Cross University Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basingstoke and North Hampshire Hospital</name>
      <address>
        <city>Basingstoke</city>
        <state>Hampshire</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <state>Kent</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arrowe Park Hospital</name>
      <address>
        <city>Wirral</city>
        <state>Merseyside</state>
        <zip>CH49 5PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <state>Strathclyde</state>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 29, 2016</study_first_submitted>
  <study_first_submitted_qc>May 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <results_first_submitted>January 25, 2021</results_first_submitted>
  <results_first_submitted_qc>April 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2021</results_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>moderate Rheumatoid Arthritis</keyword>
  <keyword>severe Rheumatoid Arthritis</keyword>
  <keyword>subcutaneous</keyword>
  <keyword>Olokizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT02760407/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment was conducted at 209 clinical sites across 18 countries (US,EU,UK, Russian Federation, Asia, Latin America). 3359 subjects were screened and 1648 subjects were enrolled (randomized). A total of 1645 subjects were treated, and 1483 subjects completed the study. A total of 1648 subjects were analyzed for efficacy in the ITT Population and 1645 subjects were analyzed for safety in the Safety Population.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Olokizumab q4w</title>
          <description>Olokizumab 64mg subcutaneous q4w+ placebo+Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 4 weeks + placebo in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)+concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Olokizumab q2w</title>
          <description>Olokizumab 64mg subcutaneous q2w + Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
        </group>
        <group group_id="P3">
          <title>Arm 3: Adalimumab q2w</title>
          <description>Active Comparator, Adalimumab 40mg q2w subcutaneous + Methotrexate&#xD;
subjects were administered adalimumab 40 mg q2w via SC injection as an active comparator +concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
        </group>
        <group group_id="P4">
          <title>Arm 4: Placebo q2w</title>
          <description>Placebo subcutaneous q2w + Methotrexate&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="479"/>
                <participants group_id="P2" count="464"/>
                <participants group_id="P3" count="462"/>
                <participants group_id="P4" count="243"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="443"/>
                <participants group_id="P2" count="421"/>
                <participants group_id="P3" count="412"/>
                <participants group_id="P4" count="207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violation of Eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>The subject was early discontinued due to lab Adverse Event as per Investigator's decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Use of prohibited Medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject didn't Completed Visits Schedule After Serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Positive Quantiferon Testing, Patient Was Not Taken Prophylactic Medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's Decision (Adverse Event)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inadequately Enrolled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal By PI's Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Did not attend treatment period visits due to misunderstanding of protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject met permanent IP discontinuation criteria, did not agree for treatment period visits</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator recorded as Sponsor's decision - decreased lymphocyte level</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Treatment Was Terminated At The Site</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Taken Out Of Study Due To Sponsor Investigating Investigational Product.</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inadequately enrolled patient refused to Follow-Up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack Of Efficacy Per PI</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient had an upper respiratory infection and took medication that was not allowed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator recorded as Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: Olokizumab q4w + Methotrexate</title>
          <description>Olokizumab 64mg subcutaneous q4w+ placebo+Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 4 weeks + placebo in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)+concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Olokizumab q2w + Methotrexate</title>
          <description>Olokizumab 64mg subcutaneous q2w + Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
        </group>
        <group group_id="B3">
          <title>Arm 3: Adalimumab q2w + Methotrexate</title>
          <description>Active Comparator, Adalimumab 40mg q2w subcutaneous + Methotrexate&#xD;
Subjects were administered adalimumab 40 mg q2w via SC injection as an active comparator+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
        </group>
        <group group_id="B4">
          <title>Arm 4: Placebo q2w + Methotrexate</title>
          <description>Placebo subcutaneous q2w + Methotrexate&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="479"/>
            <count group_id="B2" value="464"/>
            <count group_id="B3" value="462"/>
            <count group_id="B4" value="243"/>
            <count group_id="B5" value="1648"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="389"/>
                    <measurement group_id="B2" value="379"/>
                    <measurement group_id="B3" value="367"/>
                    <measurement group_id="B4" value="192"/>
                    <measurement group_id="B5" value="1327"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.7" spread="12.09"/>
                    <measurement group_id="B2" value="53.3" spread="11.92"/>
                    <measurement group_id="B3" value="54.3" spread="12.32"/>
                    <measurement group_id="B4" value="54.7" spread="11.85"/>
                    <measurement group_id="B5" value="53.9" spread="12.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="378"/>
                    <measurement group_id="B2" value="352"/>
                    <measurement group_id="B3" value="363"/>
                    <measurement group_id="B4" value="190"/>
                    <measurement group_id="B5" value="1283"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="406"/>
                    <measurement group_id="B2" value="382"/>
                    <measurement group_id="B3" value="385"/>
                    <measurement group_id="B4" value="203"/>
                    <measurement group_id="B5" value="1376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other/Mixed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.654" lower_limit="16.96" upper_limit="52.74"/>
                    <measurement group_id="B2" value="28.656" lower_limit="17.04" upper_limit="62.22"/>
                    <measurement group_id="B3" value="28.532" lower_limit="17.48" upper_limit="56.52"/>
                    <measurement group_id="B4" value="28.573" lower_limit="15.62" upper_limit="55.83"/>
                    <measurement group_id="B5" value="28.609" lower_limit="15.62" upper_limit="62.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ACR20 Response</title>
        <description>The difference between OKZ and placebo in the percentage of subjects achieving an ACR20 response and remaining on randomized treatment and in the study at Week 12. (where a responder is defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12) This endpoint will serve to demonstrate that the efficacy of OKZ is superior to placebo. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures:&#xD;
Patient Global Assessment of Disease Activity (VAS)&#xD;
Patient Assessment of Pain (VAS)&#xD;
HAQ-DI&#xD;
Physician Global Assessment (VAS)&#xD;
Level of acute phase reactant (CRP)</description>
        <time_frame>at Week 12</time_frame>
        <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Olokizumab q4w + Methotrexate</title>
            <description>Olokizumab 64mg subcutaneous q4w+ placebo+Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 4 weeks + placebo in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)+concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Olokizumab q2w + Methotrexate</title>
            <description>Olokizumab 64mg subcutaneous q2w + Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Adalimumab q2w + Methotrexate</title>
            <description>Active Comparator, Adalimumab 40mg q2w subcutaneous + Methotrexate&#xD;
Subjects were administered adalimumab 40 mg q2w via SC injection as an active comparator+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: Placebo q2w + Methotrexate</title>
            <description>Placebo subcutaneous q2w + Methotrexate&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
        </group_list>
        <measure>
          <title>ACR20 Response</title>
          <description>The difference between OKZ and placebo in the percentage of subjects achieving an ACR20 response and remaining on randomized treatment and in the study at Week 12. (where a responder is defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12) This endpoint will serve to demonstrate that the efficacy of OKZ is superior to placebo. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures:&#xD;
Patient Global Assessment of Disease Activity (VAS)&#xD;
Patient Assessment of Pain (VAS)&#xD;
HAQ-DI&#xD;
Physician Global Assessment (VAS)&#xD;
Level of acute phase reactant (CRP)</description>
          <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="479"/>
                <count group_id="O2" value="464"/>
                <count group_id="O3" value="462"/>
                <count group_id="O4" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342"/>
                    <measurement group_id="O2" value="326"/>
                    <measurement group_id="O3" value="309"/>
                    <measurement group_id="O4" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The OKZ ACR20 response rate for the 64 mg q4w treatment group at Week 12 was expected to be at least 50% resulting in an expected difference in ACR20 response rates of 25 percentage points between the respective OKZ treatment group and placebo. Sample size yield 100% disjunctive power for testing the primary hypothesis</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.270</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.183</ci_lower_limit>
            <ci_upper_limit>0.352</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The OKZ ACR20 response rate for the 64 mg q2w treatment group at Week 12 was expected to be at least 55%, resulting in an expected difference in ACR20 response rate of 30 percentage points between the respective OKZ treatment group and placebo. Sample size yield 100% disjunctive power for testing the primary hypothesis</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.258</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.171</ci_lower_limit>
            <ci_upper_limit>0.341</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR20 Response and to Demonstrate That the Efficacy of OKZ is Non-inferior to Adalimumab</title>
        <description>Where a responder is defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12. This endpoint will serve to demonstrate that the efficacy of OKZ is non-inferior to adalimumab, provided that superiority of adalimumab to placebo (assay sensitivity) is demonstrated concurrently based on the same endpoint.&#xD;
American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures:&#xD;
Patient Global Assessment of Disease Activity (VAS)&#xD;
Patient Assessment of Pain (VAS)&#xD;
HAQ-DI&#xD;
Physician Global Assessment (VAS)&#xD;
Level of acute phase reactant (CRP)</description>
        <time_frame>at Week 12</time_frame>
        <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Olokizumab q4w + Methotrexate</title>
            <description>Olokizumab 64mg subcutaneous q4w+ placebo+Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 4 weeks + placebo in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)+concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Olokizumab q2w + Methotrexate</title>
            <description>Olokizumab 64mg subcutaneous q2w + Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Adalimumab q2w + Methotrexate</title>
            <description>Active Comparator, Adalimumab 40mg q2w subcutaneous + Methotrexate&#xD;
Subjects were administered adalimumab 40 mg q2w via SC injection as an active comparator+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: Placebo q2w + Methotrexate</title>
            <description>Placebo subcutaneous q2w + Methotrexate&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
        </group_list>
        <measure>
          <title>ACR20 Response and to Demonstrate That the Efficacy of OKZ is Non-inferior to Adalimumab</title>
          <description>Where a responder is defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12. This endpoint will serve to demonstrate that the efficacy of OKZ is non-inferior to adalimumab, provided that superiority of adalimumab to placebo (assay sensitivity) is demonstrated concurrently based on the same endpoint.&#xD;
American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures:&#xD;
Patient Global Assessment of Disease Activity (VAS)&#xD;
Patient Assessment of Pain (VAS)&#xD;
HAQ-DI&#xD;
Physician Global Assessment (VAS)&#xD;
Level of acute phase reactant (CRP)</description>
          <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="479"/>
                <count group_id="O2" value="464"/>
                <count group_id="O3" value="462"/>
                <count group_id="O4" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342"/>
                    <measurement group_id="O2" value="326"/>
                    <measurement group_id="O3" value="309"/>
                    <measurement group_id="O4" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The ACR20 response rate for adalimumab was expected to be at least 52.5% at Week 12.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.224</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.148</ci_lower_limit>
            <ci_upper_limit>0.298</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A noninferiority margin of 12% was used for the comparison between OKZ and adalimumab with respect to this endpoint.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-Inferiority for each OKZ dosing regimen versus Adalimumab is achieved if the lower limit of the 97.5% confidence interval is greater than the protocol defined non-inferiority margin of -12%.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.045</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.022</ci_lower_limit>
            <ci_upper_limit>0.112</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A noninferiority margin of 12% was used for the comparison between OKZ and adalimumab with respect to this endpoint.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-Inferiority for each OKZ dosing regimen versus Adalimumab is achieved if the lower limit of the 97.5% confidence interval is greater than the protocol defined non-inferiority margin of -12%.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.034</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.035</ci_lower_limit>
            <ci_upper_limit>0.102</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between OKZ and Placebo in the Percentage of Subjects Achieving Low Disease Activity</title>
        <description>Defined as Disease Activity Score 28-joint count (DAS28) C-reactive protein (CRP) &lt;3.2, and remaining on randomized treatment and in the study at Week 12</description>
        <time_frame>at Week 12</time_frame>
        <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Olokizumab q4w + Methotrexate</title>
            <description>Olokizumab 64mg subcutaneous q4w+ placebo+Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 4 weeks + placebo in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)+concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Olokizumab q2w + Methotrexate</title>
            <description>Olokizumab 64mg subcutaneous q2w + Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Adalimumab q2w + Methotrexate</title>
            <description>Active Comparator, Adalimumab 40mg q2w subcutaneous + Methotrexate&#xD;
Subjects were administered adalimumab 40 mg q2w via SC injection as an active comparator+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: Placebo q2w + Methotrexate</title>
            <description>Placebo subcutaneous q2w + Methotrexate&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between OKZ and Placebo in the Percentage of Subjects Achieving Low Disease Activity</title>
          <description>Defined as Disease Activity Score 28-joint count (DAS28) C-reactive protein (CRP) &lt;3.2, and remaining on randomized treatment and in the study at Week 12</description>
          <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="479"/>
                <count group_id="O2" value="464"/>
                <count group_id="O3" value="462"/>
                <count group_id="O4" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="210"/>
                    <measurement group_id="O3" value="177"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The DAS28 low disease activity (based on DAS28 [CRP] &lt;3.2) response rate at Week 12 is estimated to be 10% in the placebo group and 22% in the 64 mg q4w OKZ group, resulting in an expected difference of 12 percentage points between respective OKZ group and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.330</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.255</ci_lower_limit>
            <ci_upper_limit>0.395</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The DAS28 low disease activity (based on DAS28 [CRP] &lt;3.2) response rate at Week 12 is estimated to be 10% in the placebo group and 30% in the 64 mg q2w OKZ group, resulting in an expected difference of 20 percentage points between respective OKZ group and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.325</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.250</ci_lower_limit>
            <ci_upper_limit>0.391</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between Adalimumab and OKZ in Percentage of Subjects Achieving Low Disease Activity, Defined as DAS28 (CRP) &lt;3.2</title>
        <description>Percentage of subjects achieving low disease activity, defined as DAS28 (CRP) &lt;3.2, and remaining on randomized treatment and in the study at Week 12; served to demonstrate that the efficacy of OKZ was noninferior to adalimumab, provided that superiority of adalimumab to placebo (assay sensitivity) was demonstrated concurrently based on the same endpoint</description>
        <time_frame>at Week 12</time_frame>
        <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Olokizumab q4w + Methotrexate</title>
            <description>Olokizumab 64mg subcutaneous q4w+ placebo+Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 4 weeks + placebo in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)+concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Olokizumab q2w + Methotrexate</title>
            <description>Olokizumab 64mg subcutaneous q2w + Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Adalimumab q2w + Methotrexate</title>
            <description>Active Comparator, Adalimumab 40mg q2w subcutaneous + Methotrexate&#xD;
Subjects were administered adalimumab 40 mg q2w via SC injection as an active comparator+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: Placebo q2w + Methotrexate</title>
            <description>Placebo subcutaneous q2w + Methotrexate&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between Adalimumab and OKZ in Percentage of Subjects Achieving Low Disease Activity, Defined as DAS28 (CRP) &lt;3.2</title>
          <description>Percentage of subjects achieving low disease activity, defined as DAS28 (CRP) &lt;3.2, and remaining on randomized treatment and in the study at Week 12; served to demonstrate that the efficacy of OKZ was noninferior to adalimumab, provided that superiority of adalimumab to placebo (assay sensitivity) was demonstrated concurrently based on the same endpoint</description>
          <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="479"/>
                <count group_id="O2" value="464"/>
                <count group_id="O3" value="462"/>
                <count group_id="O4" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="210"/>
                    <measurement group_id="O3" value="177"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The DAS28 low disease activity response rate for adalimumab was expected to be at least 27% at Week 12.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.256</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.191</ci_lower_limit>
            <ci_upper_limit>0.313</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A noninferiority margin of 7.5% was used for the comparison between OKZ and adalimumab with respect to this endpoint.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-Inferiority for each OKZ dosing regimen versus Adalimumab is achieved if the lower limit of the 97.5% confidence interval is greater than the protocol defined noninferiority margin of -7.5%.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.074</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.002</ci_lower_limit>
            <ci_upper_limit>0.145</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>A noninferiority margin of 7.5% was used for the comparison between OKZ and adalimumab with respect to this endpoint.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-Inferiority for each OKZ dosing regimen versus Adalimumab is achieved if the lower limit of the 97.5% confidence interval is greater than the protocol defined noninferiority margin of -7.5%.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.069</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.003</ci_lower_limit>
            <ci_upper_limit>0.141</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI)</title>
        <description>Difference between OKZ and placebo in the improvement of physical ability. Improvement of physical ability from baseline to week 12, as measured by HAQ-DI. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3 where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question.A decrease from baseline indicates improvement for HAQ-DI. The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. The HAQ-DI total score ranges from 0 to 3, with higher scores indicating greater disability.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Olokizumab q4w + Methotrexate</title>
            <description>Olokizumab 64mg subcutaneous q4w+ placebo+Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 4 weeks + placebo in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)+concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Olokizumab q2w + Methotrexate</title>
            <description>Olokizumab 64mg subcutaneous q2w + Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Adalimumab q2w + Methotrexate</title>
            <description>Active Comparator, Adalimumab 40mg q2w subcutaneous + Methotrexate&#xD;
Subjects were administered adalimumab 40 mg q2w via SC injection as an active comparator+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: Placebo q2w + Methotrexate</title>
            <description>Placebo subcutaneous q2w + Methotrexate&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI)</title>
          <description>Difference between OKZ and placebo in the improvement of physical ability. Improvement of physical ability from baseline to week 12, as measured by HAQ-DI. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3 where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question.A decrease from baseline indicates improvement for HAQ-DI. The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. The HAQ-DI total score ranges from 0 to 3, with higher scores indicating greater disability.</description>
          <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="479"/>
                <count group_id="O2" value="464"/>
                <count group_id="O3" value="462"/>
                <count group_id="O4" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.602"/>
                    <measurement group_id="O2" value="1.73" spread="0.580"/>
                    <measurement group_id="O3" value="1.72" spread="0.571"/>
                    <measurement group_id="O4" value="1.71" spread="0.616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (Visit 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="0.637"/>
                    <measurement group_id="O2" value="1.07" spread="0.654"/>
                    <measurement group_id="O3" value="1.10" spread="0.667"/>
                    <measurement group_id="O4" value="1.26" spread="0.659"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline (observed)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.592"/>
                    <measurement group_id="O2" value="-0.66" spread="0.617"/>
                    <measurement group_id="O3" value="-0.63" spread="0.594"/>
                    <measurement group_id="O4" value="-0.44" spread="0.557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.29</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR50 Response</title>
        <description>Difference between OKZ and placebo in the percentage of subjects achieving an ACR50 response and remaining on randomized treatment and in the study at Week 24 American College of Rheumatology 50% Response is a composite defined as ≥50%, improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥50%, improvement from baseline in at least 3 of the 5 remaining core set measures:&#xD;
Patient Global Assessment of Disease Activity (VAS)&#xD;
Patient Assessment of Pain (VAS)&#xD;
HAQ-DI&#xD;
Physician Global Assessment (VAS)&#xD;
Level of acute phase reactant (CRP)</description>
        <time_frame>at Week 24</time_frame>
        <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Olokizumab q4w + Methotrexate</title>
            <description>Olokizumab 64mg subcutaneous q4w+ placebo+Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 4 weeks + placebo in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)+concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Olokizumab q2w + Methotrexate</title>
            <description>Olokizumab 64mg subcutaneous q2w + Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Adalimumab q2w + Methotrexate</title>
            <description>Active Comparator, Adalimumab 40mg q2w subcutaneous + Methotrexate&#xD;
Subjects were administered adalimumab 40 mg q2w via SC injection as an active comparator+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: Placebo q2w + Methotrexate</title>
            <description>Placebo subcutaneous q2w + Methotrexate&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral,subcutaneous,or intramuscular)</description>
          </group>
        </group_list>
        <measure>
          <title>ACR50 Response</title>
          <description>Difference between OKZ and placebo in the percentage of subjects achieving an ACR50 response and remaining on randomized treatment and in the study at Week 24 American College of Rheumatology 50% Response is a composite defined as ≥50%, improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥50%, improvement from baseline in at least 3 of the 5 remaining core set measures:&#xD;
Patient Global Assessment of Disease Activity (VAS)&#xD;
Patient Assessment of Pain (VAS)&#xD;
HAQ-DI&#xD;
Physician Global Assessment (VAS)&#xD;
Level of acute phase reactant (CRP)</description>
          <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="479"/>
                <count group_id="O2" value="464"/>
                <count group_id="O3" value="462"/>
                <count group_id="O4" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240"/>
                    <measurement group_id="O2" value="234"/>
                    <measurement group_id="O3" value="214"/>
                    <measurement group_id="O4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.275</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.192</ci_lower_limit>
            <ci_upper_limit>0.349</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.278</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.195</ci_lower_limit>
            <ci_upper_limit>0.353</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.237</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.165</ci_lower_limit>
            <ci_upper_limit>0.303</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Disease Activity Index (CDAI) ≤2.8 (Remission)</title>
        <description>Difference between OKZ and placebo in the percentage of subjects with Clinical Disease Activity Index (CDAI) ≤2.8 (remission) and remaining on randomized treatment and in the study at Week 24</description>
        <time_frame>at Week 24</time_frame>
        <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Olokizumab q4w + Methotrexate</title>
            <description>Olokizumab 64mg subcutaneous q4w+ placebo+Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 4 weeks + placebo in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)+concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Olokizumab q2w + Methotrexate</title>
            <description>Olokizumab 64mg subcutaneous q2w + Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Adalimumab q2w + Methotrexate</title>
            <description>Active Comparator, Adalimumab 40mg q2w subcutaneous + Methotrexate&#xD;
Subjects were administered adalimumab 40 mg q2w via SC injection as an active comparator+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: Placebo q2w + Methotrexate</title>
            <description>Placebo subcutaneous q2w + Methotrexate&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Disease Activity Index (CDAI) ≤2.8 (Remission)</title>
          <description>Difference between OKZ and placebo in the percentage of subjects with Clinical Disease Activity Index (CDAI) ≤2.8 (remission) and remaining on randomized treatment and in the study at Week 24</description>
          <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="479"/>
                <count group_id="O2" value="464"/>
                <count group_id="O3" value="462"/>
                <count group_id="O4" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.080</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.031</ci_lower_limit>
            <ci_upper_limit>0.123</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.071</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.022</ci_lower_limit>
            <ci_upper_limit>0.113</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.089</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.046</ci_lower_limit>
            <ci_upper_limit>0.127</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All AEs were collected from the signature of the informed consent form until the last visit of the subject in the study (up to 22 weeks after the final dose of study treatment) regardless of relationship to study treatment, up to approximately 44 weeks. Any SAE with a start date after the Safety Follow-Up Period was not required to be reported unless the Investigator thought that the event might be related to either the study treatment, study treatment administration, or a protocol procedure</time_frame>
      <desc>All AEs and SAEs reported below are related to the Safety Population (safety population included all subjects who receive at least 1 dose of study treatment).&#xD;
Data for TEAEs were reported below. A Treatment Emergent Adverse Event (TEAE) is defined as an AE that started or worsened after the first dose of study treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: Olokizumab q4w + Methotrexate</title>
          <description>Olokizumab 64mg subcutaneous q4w+ placebo+Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 4 weeks + placebo in order to maintain the blind, subjects randomized to receive OKZ q4w will receive placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)+concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: Olokizumab q2w + Methotrexate</title>
          <description>Olokizumab 64mg subcutaneous q2w + Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
        </group>
        <group group_id="E3">
          <title>Arm 3: Adalimumab q2w + Methotrexate</title>
          <description>Active Comparator, Adalimumab 40mg q2w subcutaneous + Methotrexate&#xD;
Subjects were administered adalimumab 40 mg q2w via SC injection as an active comparator+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
        </group>
        <group group_id="E4">
          <title>Arm 4: Placebo q2w + Methotrexate</title>
          <description>Placebo subcutaneous q2w + Methotrexate&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="463"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="463"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="462"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Keratouveitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Latent tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma stage IV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage III</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Rheumatoid lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="463"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="183" subjects_at_risk="463"/>
                <counts group_id="E3" subjects_affected="129" subjects_at_risk="462"/>
                <counts group_id="E4" subjects_affected="71" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="477"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="463"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="462"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="477"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="463"/>
                <counts group_id="E3" events="29" subjects_affected="29" subjects_at_risk="462"/>
                <counts group_id="E4" events="18" subjects_affected="18" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="477"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="463"/>
                <counts group_id="E3" events="26" subjects_affected="26" subjects_at_risk="462"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="477"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="463"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="462"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="477"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="463"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="462"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="53" subjects_affected="53" subjects_at_risk="477"/>
                <counts group_id="E2" events="41" subjects_affected="41" subjects_at_risk="463"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="462"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="477"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="463"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="462"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="477"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="463"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="462"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="477"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="463"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="462"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="243"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="477"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="463"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="462"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="477"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="463"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="462"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="477"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="463"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="462"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="243"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any study related information could be made public available only after Sponsors written permission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elena Korneva, Senior Scientific Advisor</name_or_title>
      <organization>R-Pharm</organization>
      <phone>0074959567937 ext 3819</phone>
      <email>korneva@rpharm.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

